Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (271-280 of 440) with videos related to

Pageof 44
Sort By:
Cancer|November 28, 2018
Safety and survival outcomes for bloodless transplantation in patients with myelomaNisha S Joseph, Jonathan L Kaufman, Lawrence H Boise, et al.
Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.
Leukemia & Lymphoma|May 16, 2014
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphomaLoretta J Nastoupil, Pareen J Shenoy, Alex Ambinder, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
Blood Advances|January 4, 2018
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myelomaTineke Casneuf, Xu Steven Xu, Homer C Adams, et al.
Blood|May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaAjai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Nature Communications|April 25, 2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosisBenjamin G Barwick, Paola Neri, Nizar J Bahlis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2015
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or LymphomaJatin J Shah, Andrzej J Jakubowiak, Owen A O'Connor, et al.
Pageof 44

Showing results (271-280 of 440) with videos related to

Sort By:
Pageof 44
Cancer|November 28, 2018
Safety and survival outcomes for bloodless transplantation in patients with myelomaNisha S Joseph, Jonathan L Kaufman, Lawrence H Boise, et al.
Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.
Leukemia & Lymphoma|May 16, 2014
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphomaLoretta J Nastoupil, Pareen J Shenoy, Alex Ambinder, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
Blood Advances|January 4, 2018
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myelomaTineke Casneuf, Xu Steven Xu, Homer C Adams, et al.
Blood|May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaAjai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Nature Communications|April 25, 2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosisBenjamin G Barwick, Paola Neri, Nizar J Bahlis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2015
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or LymphomaJatin J Shah, Andrzej J Jakubowiak, Owen A O'Connor, et al.
Pageof 44